intraperitoneal fluorouracil + FOLFOX

This treatment protocol, evaluated in a Phase II clinical trial by Washington University School of Medicine, combines cytoreductive surgery (peritonectomy) with a multimodal chemotherapy regimen. It involves the repeated, delayed intraperitoneal administration of fluorouracil (5-FU) alongside systemic FOLFOX chemotherapy (a combination of oxaliplatin, leucovorin, and fluorouracil). Fluorouracil acts as a pyrimidine analog that inhibits thymidylate synthase, thereby disrupting DNA synthesis. Oxaliplatin is a platinum-based antineoplastic agent that forms DNA adducts, leading to inter- and intra-strand cross-links that inhibit DNA replication and transcription. This dual-route approach is designed to treat peritoneal surface malignancies, such as pseudomyxoma peritonei and peritoneal carcinomatosis, by providing high local concentrations of chemotherapy within the peritoneal cavity while simultaneously addressing potential systemic micrometastases.

Other names

IP 5-FU + FOLFOXIntraperitoneal 5-fluorouracil and systemic FOLFOXIntraperitoneal5-fluorouracil and systemic FOLFOXIntraperitoneal-5-fluorouracil and systemic FOLFOXIP 5FU and FOLFOX for Peritoneal MalignanciesIP5FU and FOLFOX for Peritoneal MalignanciesIP-5FU and FOLFOX for Peritoneal Malignancies